Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 11/20 | 1.00 |
| ▸ | LMNA | P02545 | 5/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 1.00 |
| ▸ | HPGD | P15428 | 4/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | RECQL | P46063 | 2/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.76 |
| ▸ | HTT | P42858 | 4/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | ESR1 | P03372 | 1/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28491328 | 0.88 | MAPT (0.79) | MAPTLMNAKDM4EHPGDHSD17B10 | |
| SCHEMBL93245 | 0.88 | MAPT (0.79) | MAPTLMNAKDM4EHPGDHSD17B10 | |
| SCHEMBL93271 | 0.86 | MAPT (1.00) | MAPTLMNAKDM4EHPGDHSD17B10 | |
| SCHEMBL10438213 | 0.85 | MAPT (0.73) | MAPTLMNAKDM4EHPGDHSD17B10 | |
| 2,3-Dihydroxy-4-Methoxy-4'-Ethoxybenzophenone SCHEMBL4007549 | 0.82 | MAPT (1.00) | MAPTLMNAKDM4EHPGDHSD17B10 | |
| SCHEMBL28694475 | 0.82 | MAPT (0.68) | MAPTLMNAKDM4EHPGDHSD17B10 | |
| SCHEMBL28439753 | 0.82 | MAPT (0.68) | MAPTLMNAKDM4EHPGDHSD17B10 | |
| SCHEMBL29415023 | 0.82 | MAPT (0.68) | MAPTLMNAKDM4EHPGDHSD17B10 | |
| SCHEMBL29696508 | 0.82 | MAPT (0.68) | MAPTLMNAKDM4EHPGDHSD17B10 | |
| SCHEMBL9639578 | 0.81 | MAPT (0.69) | MAPTLMNAKDM4EHPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220125766-A1 | METHODS FOR TREATING CONGENITAL DISORDERS OF GLYCOSYLATION | MAGGIES PEARL LLC (US) | 2022-04-28 | — | — | US | disclosed |
| US-20220125766-A1 | METHODS FOR TREATING CONGENITAL DISORDERS OF GLYCOSYLATION | MAGGIES PEARL LLC (US) | 2022-04-28 | — | — | US | disclosed |
| US-11160794-B2 | Methods for treating congenital disorders of glycosylation | MAGGIE'S PEARL, LLC (US) | 2021-11-02 | — | — | US | disclosed |
| US-11160794-B2 | Methods for treating congenital disorders of glycosylation | MAGGIE'S PEARL, LLC (US) | 2021-11-02 | — | — | US | disclosed |
| US-20210030721-A1 | METHODS FOR TREATING CONGENITAL DISORDERS OF GLYCOSYLATION | PERLARA PBC | 2021-02-04 | — | — | US | disclosed |
| US-20210030721-A1 | METHODS FOR TREATING CONGENITAL DISORDERS OF GLYCOSYLATION | PERLARA PBC | 2021-02-04 | — | — | US | disclosed |
| WO-2020040831-A1 | METHODS FOR TREATING CONGENITAL DISORDERS OF GLYCOSYLATION | PERLARA PBC (US) | 2020-02-27 | — | — | WO | disclosed |
| US-20180042899-A1 | Method of Treating Transplant Rejection and Autoimmune Diseases | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-02-15 | — | — | US | disclosed |
| US-20140050694-A1 | Method of Treating Transplant Rejection and Autoimmune Diseases | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2014-02-20 | — | — | US | disclosed |
| WO-2009081141-A1 | BENZOPHENONE COMPOUNDS | UNIVERSITY OF SHEFFIELD (GB) | 2009-07-02 | — | — | WO | disclosed |
| WO-2009081141-A1 | BENZOPHENONE COMPOUNDS | UNIVERSITY OF SHEFFIELD (GB) | 2009-07-02 | — | — | WO | disclosed |
| US-20090143279-A1 | Methods and compositions for treating metabolic disorders | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11160794-B2 | Methods for treating congenital disorders of glycosylation | MAN1B1, MAN2B1, GAA | MAPT 3244/4885LMNA 1508/4885KDM4E 3915/4885 |
| US-20090143279-A1 | Methods and compositions for treating metabolic disorders | PC, PCK2, CS | MAPT 357/4885LMNA 1929/4885KDM4E 3739/4885 |
| US-20210030721-A1 | METHODS FOR TREATING CONGENITAL DISORDERS OF GLYCOSYLATION | MAN1B1, MAN2B1, GAA | MAPT 3244/4885LMNA 1508/4885KDM4E 3915/4885 |
| US-20220125766-A1 | METHODS FOR TREATING CONGENITAL DISORDERS OF GLYCOSYLATION | MAN1B1, MAN2B1, GAA | MAPT 3244/4885LMNA 1508/4885KDM4E 3915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.